Opinion|Videos|January 24, 2025
GOLD 2025 Report: Prebronchodilator Spirometry and Diagnosis of COPD
Panelists discuss the initial thought that postbronchodilator spirometry would help differentiate chronic obstructive pulmonary disease (COPD) from asthma. However, postbronchodilator spirometry adds time and effort, as well as exposing a patient to short-term medication that may have adverse effects. Guidelines favor a fixed ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC; < 0.7) because of the ratio’s simplicity and is independent of other reference values.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Why is postbronchodilator spirometry no longer recommended in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report as the first step in confirming a diagnosis of COPD?
- How do the results of prebronchodilator spirometry further guide a COPD diagnosis?
- Why do the guidelines favor a fixed FEV1/FVC ratio (<0.7) over a lower limit of normal as a diagnostic criterion for COPD?
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Advertisement
Advertisement
Trending on HCPLive
1
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
2
Targeting the Disease Mechanism in PFIC, With Hisamitsu Hayashi, PhD
3
Residual Asthma Exacerbations on Biologics Vary by Mechanism
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5